ACRS241220C9000
- 0.00
- 0.000.00%
Aclaris Therapeutics Newsroom
Aclaris Therapeutics Upgraded to Buy From Hold at Jefferies
Aclaris Therapeutics Upgraded to Buy From Neutral at BTIG
This Healthcare Stock Is Soaring Following Exclusive License Agreement Announcement
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Aclaris Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging Promising Pipeline Developments
Aclaris Therapeutics Up 53%; Analysts' Target Boosts Follow Monday License News
Top Midday Gainers
Trending Stocks Today | Volato Group Soars 108.72%
November 19th - US stocks trending in regular trading hours.Gainers: $Volato Group(SOAR.US)$ surges 108.72% to $0.44 with a turnover of $359.78 million. $PainReform(PRFX.US)$ shoots up 145.79% to $1.3
This BioNTech Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Aclaris Therapeutics Price Target Raised to $7.00/Share From $2.00 by Leerink Partners
Aclaris Therapeutics Raised to Outperform From Market Perform by Leerink Partners
ACRS Stock Up on Licensing Deal With Biosion for Two Immunology Drugs
A Quick Look at Today's Ratings for Aclaris Therapeutics(ACRS.US), With a Forecast Between $3 to $13
Jefferies Upgrades Aclaris Therapeutics to Buy, Price Target Is $7
Piper Sandler: Authorized trade is transformative. Target price for Aclaris (ACRS.US) is significantly raised to $13.
Piper Sandler upgraded Aclaris's rating from "neutral" to "shareholding" and significantly raised the target price from $3 to $13.
Express News | Aclaris Therapeutics Inc : Btig Raises to Buy From Neutral
Aclaris Therapeutics Analyst Ratings
Aclaris Therapeutics Shares Spike Higher; Piper Sandler Upgrads Stock To Overweight With $13 Target Following Biosion Deal; Highlights Pipeline For Atopic Dermatitis And I&I Market, Catalysts Expected In 2025 Trials
Express News | Biosion- to Receive Over $40 Million Cash Payment and 19.9% Aclaris Shares
Biosion Announces Exclusive, Global License Agreement With Aclaris Therapeutics on Two Potential First-in-Class and Best-in-Class Immunology Assets